The effects of active nutritional support to patients with head and neck cancer during concurrent chemoradiotherapy

The effects of active nutritional support to patients with head and neck cancer during concurrent chemoradiotherapy - The effects of active nutritional support to patients with head and neck cancer during concurrent chemoradiotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004738

Enrollment

Registered

2010-12-16

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head and neck cancer(nasopharyngeal carcinoma, oropharyngeal carcinoma, hypopharyngeal carcinoma, supraglottic laryngeal carcinoma, cancers of the oral cavity)

Interventions

For the interventional group, daily nutritional energy will be calculated by multiplying the BEE by the activity factor (1.2) and the stress factor (1.5). The calculated energy will be administered b

#9415

) will be supplied in the case of insufficient intake. For the control group, daily nutritional energy will be calculated by multiplying the BEE by the activity factor (1.2) and the stress factor (1.1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)patients with head and neck cancer (nasopharyngeal carcinoma, oropharyngeal carcinoma, hypopharyngeal carcinoma, oral cavity carcinoma, supraglottic carcinoma) 2)clinical stage: II, III, IVA, IVB 3)PS=0, 1, 2 4)Leukocyte count>3,000/mm3 5)Platelet count>10x104/mm3 6)Hemoglobin>10g/dL 7)AST(GOT)<2.0 times the upper limit of normal at hospital 8)ALT(GPT)<2.0 times the upper limit of normal at hospital 9)Total bilirubin<3.0mg/dL 10)Creatinine<1.3mg/dL 11)Patients whose prognosis will be over 3 months 12)Patients who fully understand the study procedures and have given voluntary written informed consent after a full explanation is given

Exclusion criteria

Exclusion criteria: 1)Patients with ileus 2)Patients with no residual intestinal function 3)Patients with severe liver disorder or renal disorder 4)Patients with abnormal glucose metabolism such as severe diabetes mellitus : HbA1c > 7.0% 5)Patients with congenital disorders of amino acid metabolism 6)Patients with allergy to any ingredient of milk 7)Patients with electrolyte metabolism 8)Patients with hemophilia 9)Patients who were given a blood transfusion within 1 month 10)Pregnant women, women suspected of being pregnant, or lactating women

Design outcomes

Primary

Measure	Time frame
Percent change of body weight loss during chemoradiotherapy	—

Secondary

Measure	Time frame
1)Physical examination, blood test 2)immune status index 3)treatment completion rate 4)occurrence of adverse events	—

Countries

Japan

Contacts

Public ContactHirokazu Uemura, Susumu Nakahara

Osaka Medical Center for Cancer and Cardiovascular Diseases Department of Otolaryngology, Head and Neck Surgery

06-6972-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026